Skip to main content
. 2019 Jul 24;19(9):1013–1022. doi: 10.1016/S1473-3099(19)30266-X

Figure 2.

Figure 2

Vaccine-associated antibody responses.

Antibody responses for each dose are shown for available specimens from the modified intention-to-treat population. (A) shows the geometric mean endpoint titre (95% CI error bars) and the proportion of participants who developed antibodies against Middle East respiratory syndrome (MERS) coronavirus determined by S1-ELISA. B shows the geometric mean endpoint titre (95% CI error bars) and the proportion of participants who developed neutralising antibodies against MERS coronavirus determined by EMC-2012 MERS-coronavirus infection of Vero cells.

HHS Vulnerability Disclosure